EGFR tyrosine-kinase inhibitors (TKIs) have now been firmly established as the first-line
treatment for non-small-cell lung cancer (NSCLC) patients harboring activating EGFR …

Introduction Non-small cell lung cancer (NSCLC) is a highly lethal disease. During the past
20 years, the epidermal growth factor receptor (EGFR) has been a relevant target for …

Dacomitinib is a second-generation EGFR tyrosine kinase inhibitor (TKI) that irreversibly
binds to and inhibits EGFR/Her1, Her2 and Her4 subtypes with an efficacy comparable to …

Systemic treatment of advanced non-small cell lung cancer (NSCLC) has undergone
remarkable changes in the last decade, with the introduction of targeted therapies and …

Dacomitinib is a second-generation, irreversible, covalent pan-HER tyrosine-kinase inhibitor
(TKI). It showed potent EGFR signaling inhibition in experimental models, including first …

Introduction: Different EGFR tyrosine kinase inhibitors (TKIs) are currently approved for the
first-line treatment of NSCLC patients with EGFR mutations. Dacomitinib is an orally …

© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2018; 7
(Suppl 2): S100-S102 tlcr. amegroups. com proportion of patients who achieved and …

Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …

Background Dacomitinib irreversibly inhibits EGFR, HER2 and HER4, and showed superior
activity versus reversible EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer …

The use of targeted therapy in the management of epidermal growth factor receptor (EGFR)-
mutated non-small-cell lung cancer is an important milestone in the management of …